NICE has recommended mirvetuximab soravtansine for resistant ovarian cancer, citing better survival and a less burdensome treatment experience.

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...

Persistent fatigue, sugar cravings and irregular periods are often blamed on stress or a hectic lifestyle. However, doctors ...

"One of the most amazing things I’ve ever seen," clinician-scientist Samuel Hume wrote alongside a video clip posted on X.

A £600 million tranche of government funding for a key part of the UK's life sciences strategy – expanding the country's ...

"If you are diagnosed with Polyendocrine Metabolic Ovarian Syndrome, it doesn't mean that you are destined to have poor ...

“For anyone quietly carrying this heartbreak, you’re not alone.” ...

New science links poor sleep habits to severe long-term health risks. Five leading wellness experts break down the steps you ...

Suborbital spaceflight company Virgin Galactic has announced plans to conduct a crewed research mission in 2027 that will ...

For the first time in several election cycles, national Democrats are planning to pump resources into Texas. Several GOP-led ...

It is the first time in several election cycles National Democrats are pumping resources into Texas. An impasse in the ...